“Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s379, https://doi.org/10.25251/skin.8.supp.379.